As part of Unilabs York Bioanalytical Solutions’ (Unilabs YBS) commitment to providing an unparalleled service to its clients, YBS is pleased to announce the opening of a new facility on the Discovery Park in Sandwich Kent. The new facility will offer discovery
bioanalysis and biotransformation services.

As a key element of this new service Unilabs YBS is proud to announce the recruitment of key expertise in drug discovery bioanalysis and biotransformation. Dr Angus Nedderman will head up the Unilabs YBS Discovery Park facility and along with his team
of experienced scientists brings a wealth of experience gained with Pfizer at their Sandwich facility.

Unilabs YBS has worked with Pfizer to establish this new and exciting Discovery Park based service which will support Neusentis, Pfizer’s new Cambridge based research centre with discovery bioanalysis in addition to biotransformation services for Pfizer’s
global operations. Unilabs YBS also plan to offer this exciting new Sandwich based discovery and biotransformation service to other pharmaceutical and biotechnology companies.

Dr Nedderman stated: "We look forward to offering the level of scientific excellence we have been used to at Pfizer; utilising experienced scientists, cutting edge technology and modern laboratory facilities previously designed and built to an exceptional standard as part of the Pfizer Sandwich facilities. We will provide rapid, fit-for-purpose bioanalytical data in support of in vitro and in vivo discovery studies as well as a full metabolite characterisation service from early discovery to late development, using a range of
technologies including triple quadrupole, time-of-flight and ion trap mass spectrometry, high resolution LC, NMR and radiochemical detection."

Dr Yvonne Lech, Head of Unilabs Drug Development Services group commented: "We are extremely proud to welcome Dr Nedderman and his team to Unilabs YBS and look forward to offering this new and exciting service to our customers. Unilabs is committed to giving this highest quality of service to our customers and believe that Dr Nedderman’s expertise in biotransformation science will complement our bioanalytical and biomarker services".

Since launch in 1999 and becoming part of the Unilabs group in 2008, Unilabs York Bioanalytical Solutions has grown to become the largest, independent provider of bioanalytical services in Europe, offering pharmaceutical and biotech companies an unprecedented standard of service. The company specialises in analysing drug concentrations (large and small molecules) in body fluids, biomarker analysis and sample logistics; an essential part of the drug development process.